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AbstrAct
Patients with a limited life expectancy use 
many medications, some of which may be 
questionable.
Objectives  To identify possible solutions for 
difficulties concerning medication management 
and formulate recommendations to improve 
medication management at the end of life.
Methods  A two-round Delphi study with 
experts in the field of medication management 
and end-of-life care (based on ranking in the 
citation index in Web of Science and relevant 
publications). We developed a questionnaire 
with 58 possible solutions for problems 
regarding medication management at the 
end of life that were identified in previously 
performed studies.
results  A total of 42 experts from 13 
countries participated. Response rate in the first 
round was 93%, mean agreement between 
experts for all solutions was 87 % (range 62%–
100%); additional suggestions were given by 
51%. The response rate in the second round 
was 74%. Awareness, education and timely 
communication about medication management 
came forward as top priorities for guidelines. 
In addition, solutions considered crucial by 
many of the experts were development of a 
list of inappropriate medications at the end of 
life and incorporation of recommendations for 
end-of-life medication management in disease-
specific guidelines.
conclusions  In this international Delphi study, 
experts reached a high level of consensus 
on recommendations to improve medication 
management in end-of-life care. These findings 
may contribute to the development of clinical 
practice guidelines for medication management 
in end-of-life care.
IntrOductIOn
Patients with a limited life expectancy 
often use many medications, including 
medication prescribed for long-term 
prevention and for the treatment of 
comorbidities.1–4 When the end of life 
approaches, all medications should be 
reconsidered taking into account their 
(potential) beneficial and adverse effects, 
burden of administration and their costs. 
Physicians, nurses, patients and their 
relatives agree that inappropriate medi-
cations should be discontinued at the 
end of life.5 However, deprescribing is a 
complex process, and in clinical practice, 
a medication review and timely discon-
tinuation of potentially inappropriate 
medications (PIMs) is not self-evident.6
Recommendations have been formu-
lated for (dis)continuing PIMs at the end 
of life, such as antihyperglycemic agents, 
antimicrobials, cholinesterase inhibitors 
and bisphosphonates.7 8 Several guide-
lines are available to support physicians 
with medication management in patients 
with life-limiting disease.9 10 However, 
significant barriers still impede adequate 
medication management. Physicians 
seem to have a limited awareness of the 
issue and report a variety of reasons for 
not considering withdrawal of PIMs, 
which include low priority, uncer-
tainty about the consequences and 
avoiding confronting patients with their 
impending death.11 Apart from physi-
cian-related barriers, prominent barriers 
subsist on the level of the organisation 
of healthcare and in communication 
and collaboration between healthcare 
prioviders.12
To improve adequate medication 
management in patients with advanced 
disease, better interventions and 
evidence are needed.12 The perspectives 
on medication management and priori-
ties in end-of-life care of patients, their 
relatives, nurses and physicians, their 
roles in decision making, organisational 
aspects and communication should be 
taken into account.5 The aim of this study 
was to identify and prioritise possible 
solutions for the key impediments 
and to formulate recommendations to 
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Box 1 Definitions of concepts used in the 
questionnaires
Medication management: patient-centred care to optimise 
safe, effective and appropriate use of prescription and over-
the-counter drugs.
Medication review: an assessment of the pharmacotherapy 
based on a structural and critical evaluation of the medical, 
pharmaceutical and clinical information.
End of life: the last 3 months of life.
Patient and/or family: indicating the family especially 
when the patient is not mentally competent.
Palliative care specialist: physician or nurse specialist/
practitioner with a formal training in palliative care medicine 
or equivalent expertise due to clinical experience. (added in 
round 2)
improve medication management at the end of life. 
We consulted international experts in pharmacology 
and end-of-life care and performed a Delphi study.
MethOds
This study was conducted within the MEDIcation 
management in the LAST phase of life (MEDILAST) 
project. MEDILAST is a multicentre mixed-methods 
research project with the objective of understanding 
current medication use in the last 3 months of life 
and the associated process of decision making and 
formulating recommendations to optimise medication 
management in end-of-life care. The project is carried 
out in a collaboration of VU University Medical Center, 
Erasmus University Medical Center and Radboud 
University Medical Center in the Netherlands.
experts
A two-round Delphi survey was conducted among 
experts in the field of medication management and 
end-of-life care. Considering the scope of this Delphi 
procedure, we sought experts with a clear track record 
in palliative care and experts with a relevant back-
ground in medication management in care for the 
elderly. We aimed to include experts with different 
professional backgrounds in order to account for 
the multidisciplinary nature of palliative care. The 
selection of experts was based on ranking in the 
citation index in Web of Science (search: Palliative 
Care/Terminal Care/Hospice Care AND Medication/
Drug Utilization/Inappropriate Prescribing/Drug 
Prescriptions/Polypharmacy) and relevant publica-
tions regarding medication management. In addition, 
experts from the Dutch multidisciplinary guideline 
on polypharmacy in elderly,13 palliative care practice 
guidelines14 and palliative care expertise centers15 in 
the Netherlands were invited to participate. We aimed 
for an expert panel of about 40 experts. We used 
purposive sampling to ensure diversity of background 
and nationality. Experts who did not respond received 
a reminder e-mail 4 weeks after sending the original 
invitation. In total, 76 experts were invited, until at 
least 40 participants had given their written consent.
Questionnaire and study design
From literature and previous studies in our MEDILAST 
project (medical record review, in-depth interviews 
and a questionnaire study), barriers for adequate 
medication management at the end of life were iden-
tified.5 11 16 Based on these findings, we formulated 
possible solutions addressing these barriers. The solu-
tions were reviewed internally by our project group 
(that consists of a general practitioner (MD), internal 
medicine resident and clinical pharmacologist (EG), 
medical oncologist (LZ), anesthesiologist (BH), 
medical doctor-philosopher (WJM Dekkers) and two 
researchers in palliative care (AvdH and RP)) and pilot 
tested among colleagues, forming a list of statements 
or recommendations. These were divided in the seven 
domains that were identified in our interview study5: 
awareness and organisation (5 solutions), education 
(8), research and development (8), tools (2), roles 
(18), decision making (7) and communication (10) (see 
online supplementary appendix 1). Participants were 
provided with definitions of central concepts in this 
study (see box 1).
The Delphi study was performed in 2015. The first 
round questionnaire included 58 possible solutions. 
The experts were asked if they agreed or disagreed 
with the solutions, or they could tick ‘no answer’. 
Participants were asked to suggest modifications or 
additional solutions. Besides, experts were requested to 
answer eleven questions concerning their background.
The second round questionnaire was also reviewed 
within the project group. This questionnaire consisted 
of two parts. First, the list of solutions that resulted 
from round 1 was presented, including the items addi-
tionally suggested or adapted by the experts. The partic-
ipants were then requested to give a top 10 ranking 
score of the solutions they considered most relevant 
to formulate guidelines for medication management in 
end-of-life care (most relevant as number 1; two for 
next most relevant and so on). Second, the solutions 
discarded in the first round were presented. Experts 
could indicate if they agreed with rejection of these 
solutions, or whether they considered them crucial for 
guidelines about medication management at the end 
of life.
The questionnaires were sent by electronic mail. 
Experts were asked to respond within 4 weeks for the 
first round and within 6 weeks for the second round. A 
reminder was sent in the case of non-response within 
the given time range.
data processing
The data were processed using MS Excel 2010 (Micro-
soft Corporation, Redmond, Washington, USA). We 
defined the first round cut-off value for inclusion in 
the second round questionnaire as agreement of 75%. 
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Figure 1 Flow chart of the Delphi procedure.
Based on the top 10 ranking score given in the second 
round, a priority score was calculated (10 points 
for the first, 9 points for the second and so on) for 
each solution to provide a ranked rating of the most 
important solutions as suggested by the experts.
results
Figure 1 shows a flow chart of the Delphi process. In 
total, 76 experts were invited. Two invitations were 
returned by the recipient’s mail server as undeliverable, 
8 experts were not available or on leave, 2 considered 
themselves not an expert in the field, 2 had no time, 2 
refused because of a possible conflict of interest and 18 
did not respond. Forty-two experts agreed to collabo-
rate in our Delphi study.
round 1
The response rate was 93% (39 out of 42). The 
respondents had a mean age of 53 years (range 35–59 
years) and a mean working experience of 19 years 
(range 4–41 years). In addition, they originated from 
the Netherlands (n=19), Argentina (n=1), Australia 
(n=2), Brazil (n=1), Czech Republic (n=1), Germany 
(n=2), Israel (n=1), Italy (n=1), Northern Ireland 
(n=1), Norway (n=1), Slovenia (n=1), Sweden (n=2) 
and the USA (n=5). Of one expert, the nationality 
was unknown. Different specialties were represented: 
family medicine, nursing care, geriatrics, elderly care, 
cardiology, oncology, pulmonology, anesthesiology, 
neurology, psychiatry, pharmacy, pharmacology and 
palliative medicine. Moreover, ethicists, researchers 
and medical advisors participated. The mean level 
of agreement for 58 statements was 87.7% (median 
89.7%, range 62%–100%, SD 9.2, IQR 10.3). ‘No 
answer’ was selected by a mean of 5.9% (range 
0%–20.5%). Suggestions were given by 51.3% of 
the experts, ranging from new statements, general 
comments or experiences to adjustment of solutions 
or the vocabulary.
Because the degree of agreement was much higher 
than expected, we adjusted the cut-off value for selec-
tion of statements for the second round to the mean 
agreement found in this first round. Thirty-one solu-
tions exceeded this new cut-off point (87.7%). For 
seven of these statements, the wording was slightly 
adapted based on suggestions of the participants. 
Based on the comments in the first round a definition 
of palliative care specialist was added in the second 
questionnaire (see box 1). Twenty-seven solutions were 
deleted in the second questionnaire and 12 additional 
solutions were presented (see online supplementary 
appendix 2).
round 2
The response rate in the second round was 74% (29 
experts). One participant was on leave, one withdrew 
consent and eight experts did not respond. Only 2 
out of 43 solutions were not included in the ranking 
by any of the experts. The scores calculated for the 
different solutions ranged from 5 to 133 (mean 36.8, 
median 28). The solutions with a score above the 
average are presented in table 1. The experts graded 
solutions concerning roles, awareness, education and 
communication as most important.
Experts indicated that the physicians should 
primarily discuss the end of life and wishes, treatment 
goals and priorities regarding medication management 
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at the end of life with the patient. Awareness is consid-
ered crucial: medication management should be an 
integral part of end-of-life care and be performed duly. 
Participants agree that this should be an individualised 
process, based on the patient’s clinical situation. More-
over, they agreed that palliative care specialists should 
be available for consultation.
Specific domains that should be addressed in the 
education of healthcare professionals were mentioned. 
Physicians should be trained in communication with 
patients and their family about medication manage-
ment at the end of life. Furthermore, education in 
pharmacological treatment of symptoms at the end of 
life was considered necessary. Accordingly, education 
in medication management at the end of life should 
be part of healthcare professionals training, in resi-
dencies, fellowships, medical schools and in nursing 
schools. Besides, such education should also become 
available for healthcare professionals. The main 
concern regarding communication was that it should 
include conversations about the goals of end-of-life 
care in relation to quality of life.
Twenty-seven out of 29 experts selected one or more 
of the 27 solutions that were initially rejected in the 
first round. Solutions considered crucial for guidelines 
about medication management by more than one-third 
of the experts are presented in table 2.
Participants most frequently prioritised solutions 
regarding research and development, awareness, 
education and roles. Specific suggestions for research 
and development included incorporation of recom-
mendations for medication management at the end of 
life in disease-specific clinical practice guidelines and 
development of a list of medications that could be 
tapered or discontinued at the end of life. Regarding 
awareness, the experts stressed that physicians lacking 
experience with medication management at the end of 
life should consult a palliative care specialist. Explicit 
identification of the last phase of life was added as a 
focus for education for healthcare professionals. They 
stated that the primary treating physician is respon-
sible for recording the medication management and for 
formulating an end-of-life care plan with the patient. 
For patients residing at home, the general practitioner 
is considered to be the primary treating physician. 
Nurses should have a supportive role by providing 
information, explanation and advice to the patient and 
relatives.
dIscussIOn
This Delphi study shows that experts in palliative care 
and medication management from different profes-
sions in 13 countries agree on the most important 
issues concerning medication management at the end 
of life. Key solutions indicated by the experts concern 
the central role of the physician in medication manage-
ment, necessity of awareness on medication manage-
ment at the end of life, the need for education on 
medication management for healthcare workers and 
trainees and the importance of timely communication 
with the patient and family in the process of medica-
tion management.
Main findings
Physicians’ awareness of medication management
This Delphi study makes clear that, according to 
experts, the physician has a central role in medica-
tion management at the end of life. Two highly ranked 
solutions indicate that it is up to the physicians to 
discuss the medication and do this evaluation with 
patients in a timely manner. The urge for attention on 
a medication review and discussion with the patient is 
in line with several studies indicating the high preva-
lence of PIMs used by patients at the end of life.2 17 
Physicians do affirm that patients at the end of life 
use too many medications and that they should not 
use PIMs,18 but apparently discontinuation of PIMs is 
still not standard practice. As Anderson et al discuss 
in their study, awareness on PIMs refers to the level 
of insight a prescriber has into the appropriateness of 
his or her prescribing. They found that poor insight 
was an observed rather than reported barrier and that 
prescriber beliefs at a population level did not neces-
sarily translate to prescribing practices for the indi-
vidual patient.19 Similar findings came forward in an 
interview study on views of patients, relatives, nurses 
and physicians on medication management at the end 
of life.5 Although all involved parties agreed that PIMs 
should be discontinued and that in this process physi-
cians should take the lead, a medication review was 
generally not a matter of course. These findings, alto-
gether with the five recommendations of the experts 
of this Delphi study regarding education, urgently call 
for education on medication management in end-of-
life care.
Timely communication
Multiple factors are described in literature as depre-
scribing barriers explaining the discrepancy between 
the ideal situation and practice, like lack of time, estab-
lished beliefs in the benefits and harms of medication 
use, unknown consequences of withdrawing medi-
cations and avoidance of negative consequences.5 20 
Even more importantly, physicians need to recognise 
a limited life expectancy of their patient and initiate 
end-of-life conversations as a prerequisite for deci-
sion-making conversations.21 Hancock et al describe 
that many healthcare professionals express discom-
fort at having to broach the topic of a limited prog-
nosis and may withhold information or not disclose 
prognosis. These difficulties perceived by healthcare 
professionals in regard of speaking to patients with 
limited life expectancy may act as a barrier towards 
discontinuing medication.2 Conforming to these 
barriers in communication, experts in our Delphi 
study stress the importance of communication with 
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Table 1 Top 15 solutions based on their ranking score (and their category)
Solution Score
1 Physicians should discuss the wishes, treatment goals and priorities regarding medication management at the end of life with the 
patient in a timely manner. (Roles)
133
2 A medication review should be an integral part of the care for patients at the end of life. (Awareness) 130
3 Physicians should discuss the end of life with the patient in a timely manner. (Roles) 90
4 Medication management at the end of life should be individualised, based on the patient's clinical situation. (Awareness – newly 
added in round 1)
89
5 Healthcare professionals should be trained in communicating with patients and/or their family about decision making on medication 
management at the end of life. (Education)
74
6 Education in medication management at the end of life should be incorporated in all medical training (nursing school, medical 
students, residencies and fellowships). (Education – newly added in round 1)
71
7 It should be discussed with the patient and/or family that the goal of medication management at the end of life is improving/
maintaining the quality of life. (Communication)
70
8 Education in medication management at the end of life should be organised for healthcare professionals. (Education) 61
9 Healthcare professionals should be trained in the pharmacological treatment of symptoms at the end of life. (Education) 60
10 Palliative care specialists should be available for consultation regarding medication management for patients at the end of life. 
(Awareness)
56
11 A list of drugs with a high risk of inappropriateness at the end of life should be developed. (Research) 54
12 In communicating about medication management at the end of life nurses and physicians should take into account the norms and 
values of the patient and/or family. (Communication)
52
13 It should be discussed with the patient and/or family how the medication can be adjusted at the end of life and what can be 
expected of these changes. (Communication)
37
14 Patient or proxy based assessment tools (eg, ESAS, EORTC, symptom diary, PPS and PPI) should be used to aid symptom assessment 
and treatment at the end of life. (Tools)
36
14 At the end of life each drug should be revised for its potential congruence with the clinical aims of the specific situation in a specific 
patient. (Research – newly added in round 1)
36
EORTC, European Organization for Research and Treatment of Cancer ; ESAS, Edmonton Symptom Assessment Scale; PPI, Palliative Prognostic Index; PPS, 
Palliative Performance Scale.
Table 2 First round solutions selected by more than one-third of experts not to be rejected
Solution Score
1 In current treatment guidelines (eg, for hypertension, heart failure and diabetes) recommendations for medication management at the 
end of life should be incorporated. (Research)
20
2 A list of drugs that could be tapered off or discontinued at the end of life under certain conditions should be developed (eg, 
anticoagulant, antihypertensive, blood glucose lowering, antibiotic, antipsychotic, antidepressant or anticonvulsive drugs). (Research)
17
3 Physicians lacking experience with medication management at the end of life should consult a palliative care specialist. (Awareness) 16
4 Marking of the end of life should be part of education for healthcare professionals. (Education) 12
The primary treating physician should formulate an end-of-life care plan with the patient and/or family. (Roles) 12
The general practitioner is the primary treating physician when the patient resides at home. (Roles) 12
5 The primary treating physician is responsible for recording the medication management at the end of life. (Roles) 10
Nurses should contribute to medication management at the end of life by providing information, explanation and advice to the patient 
and/or family. (Roles)
10
patients and/or their family about decision making on 
medication management at the end of life and the need 
for training of healthcare professionals specifically in 
communication concerning this topic.
strengths and limitations
A strength of our study is the systematic and rigorous 
approach adopted in this Delphi procedure22 and the 
inclusion of views of experts from all over the world 
and coming from primary care, hospital and hospice 
care. The response was satisfactory, namely 93% in the 
first Delphi round and 74% for the second round.
There were some limitations. First, since half of the 
consulted experts were Dutch, solutions may have 
been biased towards those relevant for the healthcare 
system in the Netherlands. However, in both rounds 
of the Delphi study, there appeared to be a high degree 
of consensus among all experts. Although experts of 
different professions participated and the average 
length of working experience (19 years) suggests 
that our panel represents a broad and experienced 
group, it is not possible to determine if the panel is 
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representative of the population of palliative care and 
medication management experts.
Second, a pre-Delphi survey or focus group might 
have contributed to prepare the first survey of our 
Delphi study to address the study aim. Third, the 
consensus for the first round was predefined as 75% 
agreement, a cut-off common according to acknowl-
edged Delphi guidelines.23 The high degree of 
consensus in our study (87.7%) drove us to redefine 
the cut-off point. The exact limit could be a matter of 
discussion.
Finally, the definition of palliative care specialist 
(box 1) does not allow for specialist palliative care 
pharmacists or other healthcare professionals who 
have an integral role in medication management at 
end of life.
What this study adds
Before starting the MEDILAST project, no compre-
hensive evidence-based guidelines for medication 
management in end-of-life care were available.24 Many 
tools and guidelines are available to manage medica-
tion for the aged, for example, the Beers criteria,25 26 
STOPP (Screening Tool of Older Person's Prescrip-
tions) and START (Screening Tool to Alert doctors 
to Right Treatment) criteria27 and the Medication 
Appropriateness Index.28 Meanwhile, the OncPal 
deprescribing guideline9 and Screening Tool of Older 
Persons Prescriptions in Frail adults with limited life 
expectancy (STOPPfrail)10 were published. Lindsay 
et al developed the OncPal deprescribing guideline 
to assist in discontinuation of specific medications or 
medication classes (like aspirin, dyslipidaemia medica-
tions and antihypertensives) in patients with advanced 
cancer.9 Lavan and colleagues10 published the STOP-
Pfrail, a list of 27 criteria determined in a Delphi 
consensus survey. The criteria relate to medications 
that are potentially inappropriate in frail older patients 
with limited life expectancy and may assist physicians 
in deprescribing medications in these patients. Our 
Delphi study indicates that translation of these tools 
into practice as a deprescribing guideline will also need 
to address the other steps of the deprescribing process, 
like communication about treatment goals, planning 
medication withdrawal (tapering if required), moni-
toring and follow-up after cessation.
Experts in our study gave specific suggestions for 
research and development. Whereas a substantial part 
of medications in end-of-life care are prescribed for 
comorbid diseases,16 there is an urge for reflection on 
how to manage those medications at the end of life and 
to address this issue in treatment guidelines. Pharma-
cological guidelines rarely give any recommendations 
for discontinuation. Experts in our study suggested 
research investigating discontinuation or tapering off 
medications at the end of life under certain conditions, 
for example, in chronic conditions like diabetes and 
cardiovascular disease. Koekkoek et al29 give a good 
example of how to deal with oral anticonvulsants in 
the end of life of patients with glioma who develop 
swallowing difficulties. Although this applies to a 
very specific patient group, their suggestions could be 
extrapolated to other populations.
cOnclusIOns
Experts in the field of medication management and 
end-of life care from 13 countries reached a high 
level of consensus on a number of important recom-
mendations to improve medication management at 
the end of life. Key issues indicated by the experts 
concern the central role of the physician in medica-
tion management, necessity of awareness on medi-
cation management at the end of life; the need for 
education on medication management for healthcare 
workers and trainees; and the importance of commu-
nication with the patient and family in the process of 
medication management. These indications comple-
ment the elements provided in the existing tools for 
medication management. Research is needed to facil-
itate medication management in end-of-life care to 
develop a list of medications inappropriate in end-of-
life care and incorporation of recommendations for 
end-of-life medication management in disease-spe-
cific guidelines. A best practice for medication 
management in end-of-life care including specific 
guidelines for particular medications and recommen-
dations regarding decision making and communica-
tion should be elaborated.
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